Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales in 2024 of the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea, in the total amount of approximately CHF 2.2 million.
For Cresemba, this comprises a milestone payment for sales in Canada, by AVIR Pharma Inc, as well as the first sales milestone payment for the Middle East and North Africa (MENA) region, by Hikma Pharmaceuticals LLC. For Zevtera, this reflects a milestone payment in Europe, by Advanz Pharma.
David Veitch, Chief Executive Officer, said: 'We are very pleased with the commercial progress of our two commercialized brands in Canada, the MENA region and Europe. Their continued growth confirms that Cresemba and Zevtera are serving significant medical needs around the world.'
Basilea's commercial partnerships cover well over 100 countries worldwide. By year-end 2024, Cresemba was marketed in more than 70 countries while Zevtera was marketed in 20 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1
About Cresemba® (isavuconazole)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®. In Canada, Cresemba is approved for use in adults and pediatrics from 1 year up to 18 years for the treatment of invasive aspergillosis and invasive mucormycosis.2 In countries of the MENA region, it is indicated in adults for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate. Isavuconazole is also approved in the United States (US),3 the EU4 and several additional countries in Europe and beyond, including Japan and China.5
About Zevtera® (ceftobiprole medocaril sodium)
Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.6 In several countries in Europe, the brand is approved as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP).6 Zevtera is also approved in the United States7, 8, China and several other countries.5
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland
Phone
+41 61 606 1102
media_relations@basilea.cominvestor_relations@basilea.com
This press release can be downloaded from www.basilea.com.
References
IQVIA Analytics Link, September 2024. In-market sales reported as moving annual total (MAT) in US dollar.
Health Canada, Cresemba® (isavuconazole) Product Monograph: https://pdf.hres.ca/dpd_pm/00077745.PDF [Accessed: January 27, 2025]
Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: January 27, 2025]
European Public Assessment Report (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: January 27, 2025]
The registration status and approved indications may vary from country to country.
Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: January 27, 2025]
Full US prescribing information: https://www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk
Basilea's ceftobiprole phase 3 program is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. Basilea has been awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.
Attachment
Press release (PDF)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
43 minutes ago
- Business Wire
IFF Launches POWERFRESH ® ACE 2000, a Bread Fresh-Keeping Solution That ‘Aces' the Shelf-Life Test
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announces the launch of POWERFRESH® ACE 2000 to the U.S. market. This next-generation fresh-keeping enzyme solution is designed to help industrial bakeries deliver bread with improved softness, resilience and cohesiveness throughout shelf life — meeting specific consumer demands while improving operational efficiency. 'Developed by IFF's biosciences experts, this advancement underscores our commitment to helping bakeries deliver exceptional value and maintain a competitive edge in the industry,' said Clementina Dellomonaco, senior vice president of food biosciences at IFF. 'Whenever we enhance the consumer experience, we help our customers build stronger brand equity, drive repeat purchases and unlock long-term growth.' As ingredient prices rise and consumer expectations for long-lasting freshness continue to grow, U.S. bakeries face unprecedented pressure to maintain product quality without increasing operational strain. A recent survey shows that 60% of U.S. consumers would buy bread marketed as 'fresher for longer,' and more than half expect at least four days of freshness at purchase. 1 POWERFRESH® ACE 2000 addresses these priorities by improving softness and resilience for up to 34 days, while reducing waste and inventory complexity. In IFF-led trials, POWERFRESH® ACE 2000 demonstrated a strong performance across both white and whole-wheat bread applications. This enzyme consistently delivered superior resilience while maintaining structure and visual appeal, even at lower dosage levels compared to market alternatives, resulting in stable loaves with excellent texture and mouthfeel. Crucially, it preserved the soft, yet easy-to-butter texture that consumers prefer, even several days after purchase. 'As a staple food, bread is a regular fixture in consumers' baskets — so expectations for quality are high and constant,' said Emily Wagener, industry leader for food and beverage enzymes for North America at IFF. 'At the same time, bakeries face challenges that require smarter solutions. POWERFRESH® ACE 2000 is bakers' ally to deliver high-quality products with the delicious texture and freshness consumers expect, every time.' As the latest addition to IFF's established POWERFRESH® portfolio, this new solution offers a smarter path to consistent bread quality and efficiency — whether used in new formulations or to optimize existing ones. Improved product resilience enables industrial bakeries to extend distribution and better manage shelf-life targets. These operational gains also align with sustainability goals by reducing waste, minimizing returns and optimizing resources across the supply chain. Learn more about POWERFRESH® ACE 2000 and IFF's innovative bakery enzyme portfolio here. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. ©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Business Wire
43 minutes ago
- Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Business Wire
an hour ago
- Business Wire
Wolverine Worldwide Launches Junior Board
BUSINESS WIRE)-- Wolverine World Wide, Inc. (NYSE: WWW) today announced the launch of its inaugural Junior Board, an advisory body consisting of 11 early-career professionals responsible for elevating the voices and perspectives of the Company's emerging talent and further strengthening its culture of innovation and collaboration. Junior Board members were selected after an extensive interview process, during which they were evaluated based on leadership potential, commitment to the Company's vision and values, strategic orientation, communication, relationship building, and critical thinking skills. The group will convene monthly to address key topics and create a dynamic feedback loop intended to inspire positive change and progress, and will work directly with the Company's executive team and Chief Executive Officer. 'I am immensely proud of the new culture we are building at Wolverine Worldwide,' said Chris Hufnagel, President and CEO of Wolverine Worldwide. 'With the creation of our Junior Board, we're doubling down on our commitment to developing young talent and fostering an inclusive and collaborative workplace where everyone feels they belong and can thrive – while building a strong leadership pipeline for tomorrow.' Members of Wolverine Worldwide's Junior Board come from across the Company's offices, brands, and functions – and include: Chandler Alberda, Digital Marketing Manager, Merrell – Junior Board Chair Blake Robinson, Senior Digital Marketing Specialist, Work Group Cleo Hallan, Lead Digital Product Manager, D&TE Edith Rimmer, Retail Operations Coordinator, Sweaty Betty Heather Telfor, Human Resources Business Partner Manager, Shared Services Joe Gamino-Kirkhoff, Senior Brand Marketing Specialist, Merrell Liony Florentina, Strategic Costing Senior Analyst, Supply Chain Lucy Howard, Field Marketing Lead, Saucony Ricky Hajduk, Key Accounts Manager, Merrell Teddy Okerstrom, User Experience Research Manager, D&TE Tobias Kammerer, Color Designer, Merrell 'The Junior Board is more than a committee: it's a commitment to listen, learn, lead, and build a culture where every voice in our global organization feels valued and heard,' said Chandler Alberda, Wolverine Worldwide Junior Board Chair. 'We are excited to champion bold ideas, diverse perspectives, and fresh thinking that reflect our Company's vision to Make. Every Day. Better. ' The creation of Wolverine Worldwide's Junior Board comes on the heels of the Company receiving its first Great Place To Work® Certification ™ – underscoring its commitment to prioritizing employee experience and cultivating a strong company culture, as determined by employees' survey feedback. 88% of U.S.-based Wolverine Worldwide employees said the Company is a great workplace, 33 percentage points higher than the average company. Earlier this year, Wolverine Worldwide was also recognized by Forbes as one of America's Dream Employers and America's Best Midsize Employers, and by Inspiring Workplaces as one of the Most Inspiring Workplaces in North America. Founded in 1883, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world's leading designers, marketers, and licensors of branded casual footwear and apparel, performance outdoor and athletic footwear and apparel, kids' footwear, industrial work boots and apparel, and uniform footwear. The Company's portfolio includes Merrell®, Saucony®, Sweaty Betty®, Hush Puppies®, Wolverine®, Chaco®, Bates®, HYTEST®, and Stride Rite®. Wolverine Worldwide is also the global footwear licensee of the popular brands Cat® and Harley-Davidson®. Based in Rockford, Michigan, for more than 140 years, the Company's products are carried by leading retailers in the U.S. and globally in approximately 170 countries and territories. Wolverine Worldwide is a Great Place To Work® Certified™ company. For additional information, please visit our website,
